Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
$8.65
+0.5%
$9.26
$5.51
$11.99
$169.71MN/A49,447 shs26,207 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$7.70
-2.8%
$7.53
$4.32
$10.50
$176.98M1.55288,359 shs593,330 shs
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
$1.88
-4.6%
$1.85
$1.35
$4.40
$41.65M1.350,646 shs83,367 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$2.56
+2.8%
$1.51
$0.78
$3.39
$182.17M0.851.36 million shs844,117 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
0.00%-3.46%-11.37%+19.31%+864,999,900.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
0.00%+1.05%+5.62%-3.14%-12.00%
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
0.00%-6.00%-20.34%-6.00%+187,999,900.00%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%+4.07%+111.57%+81.56%-14.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.886 of 5 stars
3.60.00.00.02.61.70.6
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.3943 of 5 stars
3.41.00.00.03.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
3.00
Buy$20.50136.99% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
3.17
Buy$22.80196.10% Upside
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
0.00
N/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.75
Moderate Buy$10.00290.63% Upside

Current Analyst Ratings Breakdown

Latest RNTX, ACTU, INMB, and VTYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$20.00
4/22/2025
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
3/17/2025
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$50K3,539.54N/AN/A$2.07 per share3.72
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
-$24.75MN/A0.00N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%7/30/2025 (Estimated)
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
-$15.73M-$2.86N/AN/AN/AN/A-74.08%-27.93%N/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$192.96M-$1.75N/AN/AN/AN/A-54.94%-50.01%8/14/2025 (Estimated)

Latest RNTX, ACTU, INMB, and VTYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
-$0.26-$0.32-$0.06-$0.32N/AN/A
5/15/2025Q1 2025
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
-$0.21-$0.25-$0.04-$0.25N/AN/A
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
5/8/2025Q1 2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.48-$0.39+$0.09-$0.39N/AN/A
4/7/2025Q4 2024
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/A-$0.26N/A-$1.89N/AN/A
3/27/2025Q4 2024
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.54-$0.40+$0.14-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/A
1.68
1.68
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.59
2.59
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
N/A
3.30
3.30
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
23.52
23.52

Institutional Ownership

CompanyInstitutional Ownership
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
90.89%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%

Insider Ownership

CompanyInsider Ownership
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
69.34%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
5.10%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
14.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actuate Therapeutics stock logo
ACTU
Actuate Therapeutics
1019.62 millionN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
1022.98 million14.37 millionOptionable
Rein Therapeutics, Inc. stock logo
RNTX
Rein Therapeutics
922.15 million20.56 millionN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.16 million57.86 millionOptionable

Recent News About These Companies

Ventyx Biosciences reports annual meeting results
Ventyx Biosciences announces seven additional appointments to SAB
H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$8.65 +0.04 (+0.46%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$8.66 +0.01 (+0.17%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$7.70 -0.22 (-2.78%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$7.70 0.00 (0.00%)
As of 06/13/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$1.88 -0.09 (-4.57%)
As of 06/13/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

$2.56 +0.07 (+2.81%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.55 -0.01 (-0.39%)
As of 06/13/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.